ABSTRACT
Background The COVID-19 pandemic has led to over 820,000 deaths for almost 24 million confirmed cases worldwide, as of August 27th, 2020, per WHO report. Risk factors include pre-existing conditions such as cancer, cardiovascular disease, diabetes, obesity, and cancer. There are currently no effective treatments. Our objective was to complete a meta-analysis to identify comorbidity-associated single nucleotide polymorphisms (SNPs), potentially conferring increased susceptibility to SARS-CoV-2 infection using a computational approach.
Results SNP datasets were downloaded from publicly available GWAS catalog for 141 of 258 candidate COVID-19 comorbidities. Gene-level SNP analysis was performed to identify significant pathways by using MAGMA program. SNP annotation program was used to analyze MAGMA-identified genes. COVID-19 comorbidities from six disease categories were found to have significant associated pathways, which were validated by Q-Q plots (p<0.05). The top 250 human mRNA gene expressions for SNP-affected pathways, extracted from publicly accessible gene expression profiles, were evaluated for significant pathways. Protein-protein interactions of identified differentially expressed genes, visualized with STRING program, were significant (p<0.05). Gene interaction networks were found to be relevant to SARS and influenza pathogenesis.
Conclusion Pathways potentially affected by or affecting SARS-CoV-2 infection were identified in underlying medical conditions likely to confer susceptibility and/or severity to COVID-19. Our findings have implications in COVID-19 treatment development.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is not a clinical trial.
Funding Statement
No external funding for this study was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm all relevant ethical guidelines have been followed, and the present study was exempt from review as only publicly available data were used.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
ABBREVIATIONS
- ADAMTS9
- a disintegrin-like and metalloprotease with thrombospondin type 1 motif, 9
- AHABE
- adenocarcinoma human alveolar basal epithelial
- aLFC
- average log-fold change
- A-MuLV
- Abelson murine leukemia virus
- C127
- mouse fibroblast
- CIS
- confidence interaction score
- COVID-19
- coronavirus disease of 2019
- CTL
- cytotoxic T-lymphocyte
- EHMT2
- euchromatic histone lysine methyltransferase 2
- FGFR2
- fibroblast growth factor receptor 2
- GEO
- Gene Expression Omnibus
- GIDEON
- Global Infectious Disease and Epidemiology Network database
- GO
- Gene Ontology
- GWAS
- genome-wide association studies
- HBE
- human bronchial epithelial
- HEK
- human embryonic kidney
- HLA-DRB1
- major histocompatibility complex, class II, DR Beta 1
- HLA-DRB5
- major histocompatibility complex, class II, DR Beta 5
- HLA-DQA2
- major histocompatibility complex, class II, DQ Beta 1
- HLA-DQB1
- major histocompatibility complex, class II, DQ Beta 1
- HTL
- helper T-lymphocyte
- HUGO
- Human Genome Organization
- IFI30
- IFI30 lysosomal thiol reductase
- IL2RA
- interleukin 2 receptor subunit alpha
- KEGG
- Kyoto Encyclopedia of Genes and Genomes
- KPNB1
- karyopherin subunit beta 1
- MAGMA
- Multi-marker Analysis of GenoMic Annotation
- MDCK
- madin-darby canine kidney
- miRDB
- microRNA Target Prediction Database
- ND
- No Data
- NUP153
- nucleoporin 153
- NUP160
- nucleoporin 160
- PBMCs
- peripheral blood mononuclear cells
- PIK3R2
- phosphoinositide-3-kinase regulatory subunit 2
- PM
- primary macrophages
- PPARGC1A
- peroxisome proliferator-activated receptor gamma coactivator 1 alpha
- PolyPhen2
- Polymorphism Phenotyping 2
- Q-Q
- quantile-quantile
- SARS
- severe acute respiratory syndrome
- SARS-CoV-1
- severe acute respiratory syndrome coronavirus-1
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus-2
- SIFT
- Sorting Intolerant from Tolerant
- SLC4A7
- solute carrier family 4 member 7
- SLC24A3
- solute carrier family 24 member 3
- SNPs
- single nucleotide polymorphisms
- ST6GALNAC1
- ST6-acetylgalactosaminide alpha-2,6-sialytransferase 1
- ST6GALNAC3
- ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3
- STAT1
- signal transducer and activator transcription 1
- STAT3
- signal transducer and activator of transcription 3
- TAP2
- transporter 2, ATP binding cassette subfamily B member
- VEP
- Variant Effect Predictor
- Vero
- epithelial kidney cells derived from African green monkey (Chlorocebus spp.);
- WHO
- World Health Organization
- ZAP-70
- zeta-chain associated protein kinase 70
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.